ZEOX · Zeo ScientifiX, Inc. · Congressional Trades
Substantial doubt about the company's ability to continue as a going concern.
“As of April 30, 2026, based on the factors described above, the Company concluded that there was substantial doubt about its ability to continue to operate as a going concern for the 12 months following the issuance of these financial statements. In addition, the Company's independent registered public accounting firm, in its report on the Company's October 31, 2025 financial statements, has expressed substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Jun 15, 2026
One customer — 14.2% of revenue (the six months ended April 30, 2026)
“During the six months ended April 30, 2026, the Company sold products and services totaling approximately $571,000 (14.2%) to a large medical practice group and distributor”
One customer — 12.7% of revenue (the six months ended April 30, 2026)
“and approximately $511,000 (12.7%) to another large medical practice group and distributor.”
One customer — 15.2% of revenue (the six months ended April 30, 2025)
“$341,000 (15.2%)”
One customer — 12.1% of revenue (the six months ended April 30, 2025)
“During the six months ended April 30, 2025, the Company sold products and services totaling approximately $270,000 (12.1%) to a large distributor”
One customer — 10.2% of revenue (the six months ended April 30, 2025)
“and $228,000 (10.2%) to two individual medical practices.”
Transactions in this listed security by members of the U.S. Congress, disclosed under the STOCK Act. Lawmakers must report trades within 45 days, so the filing date can lag the trade itself.
No Congressional Trades
No congressional trading data is available for this listed security yet.